These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8431510)

  • 21. Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation.
    Capucha V; Mendes E; Francisco AP; Perry MJ
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6903-8. PubMed ID: 23041157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
    Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
    Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
    Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
    J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
    Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
    J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of cyclosporine on immunogenicity of a bacterial enzyme carboxypeptidase G2 in ADEPT.
    Sharma SK; Bagshawe KD; Melton RG; Begent RH
    Transplant Proc; 1996 Dec; 28(6):3154-5. PubMed ID: 8962222
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of prodrug, active drug, and metabolites in an ADEPT clinical study.
    Springer CJ; Poon GK; Sharma SK; Bagshawe KD
    Cell Biophys; 1993; 22(1-3):9-26. PubMed ID: 7889545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-directed enzyme/prodrug therapy (ADEPT).
    Bagshawe KD
    Biochem Soc Trans; 1990 Oct; 18(5):750-2. PubMed ID: 2083666
    [No Abstract]   [Full Text] [Related]  

  • 29. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
    Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
    Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme and proton-activated prodrugs for a selective cancer therapy.
    Tietze LF; Feuerstein T
    Curr Pharm Des; 2003; 9(26):2155-75. PubMed ID: 14529411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy.
    Jung M
    Mini Rev Med Chem; 2001 Nov; 1(4):399-407. PubMed ID: 12369965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor effects of antibody enzyme conjugates in combination with prodrugs.
    Senter PD
    Front Radiat Ther Oncol; 1990; 24():132-41; discussion 161-5. PubMed ID: 2341048
    [No Abstract]   [Full Text] [Related]  

  • 34. Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2.
    Melton RG; Boyle JM; Rogers GT; Burke P; Bagshawe KD; Sherwood RF
    J Immunol Methods; 1993 Jan; 158(1):49-56. PubMed ID: 8429216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Trends in
    Sun IC; Yoon HY; Lim DK; Kim K
    Bioconjug Chem; 2020 Apr; 31(4):1012-1024. PubMed ID: 32163277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
    Dowell RI; Springer CJ; Davies DH; Hadley EM; Burke PJ; Boyle FT; Melton RG; Connors TA; Blakey DC; Mauger AB
    J Med Chem; 1996 Mar; 39(5):1100-5. PubMed ID: 8676345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-directed enzyme-prodrug therapy.
    Pedley RB; Sharma SK; Hawkins RE; Chester KA
    Methods Mol Med; 2004; 90():491-514. PubMed ID: 14657581
    [No Abstract]   [Full Text] [Related]  

  • 39. Strategies for enzyme/prodrug cancer therapy.
    Xu G; McLeod HL
    Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Niculescu-Duvaz I; Cooper RG; Stribbling SM; Heyes JA; Metcalfe JA; Springer CJ
    Curr Opin Mol Ther; 1999 Aug; 1(4):480-6. PubMed ID: 11713763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.